1st Aug 2022 – Glycostem Therapeutics B.V., a leading clinical-stage company focused on the development of therapeutic allogeneic off-the-shelf Natural Killer (NK) cells, and medac GmbH, an international pharmaceutical company based in Germany, will partner to commercialize Glycostem’s lead product, oNKord®.
Glycostem and medac enter into license, manufacturing, supply and commercialization agreement for Glycostem’s lead product - oNKord®
Glycostem announces new data presentation at EHA 2022 Congress highlighting early safety and clinical course of oNKord® in patients with Acute Myeloid Leukemia
13th May 2022 – Glycostem Therapeutics B.V., a leading clinical-stage company focused on the development of therapeutic allogeneic off-the-shelf Natural Killer (NK) cells, today announced that an abstract on further findings of patients treated in its phase I/IIa WiNK trial have been acce
Glycostem announces initial clinical data to be presented at 2021 ASH Annual Meeting
4th November 2021 – Glycostem Therapeutics B.V., a leading clinical-stage company focused on the develop
Glycostem donates funding to the Acute Leukemia Advocates Network and Leukaemia Care
11th May 2021 – Glycostem Therapeutics B.V., a leading clinical-stage company focused on the development of therapeutic allogeneic off-the-shelf Natural Killer (NK) cells, announced the donation to the Acute Leukemia Advocates Network (ALAN) and to Leukaemia Care.
Glycostem enters into Material Transfer Agreement with Pieris to enhance solid tumor targeting capabilities of Glycostem’s oNKord® and CAR-NK treatments
12th March, 2021 – Glycostem Therapeutics B.V., a leading clinical-stage company focused on the development of therapeutic allogeneic off-the-shelf
Glycostem and Ghent University sign license agreement on NK cell therapy technology
17th December, 2020 - Glycostem Therapeutics and Ghent University (UGent) have signed a license agreement for an inn
Glycostem announces treatment of first patient in pivotal phase I/IIa trial
15th December, 2020 – Glycostem today announced that the first patient has been dosed in its pivotal phase I/IIa trial of oNKord® for th
Glycostem initiates phase I/IIa trial of oNKord® in patients with Acute Myeloid Leukemia
20th November 2020 – Glycostem today announced the
FDA grants Glycostem’s oNKord® Orphan Drug Designation for Multiple Myeloma
12th October 2020 - Glycostem announces it has received the FDA’s Orphan Drug Designation (ODD) for treatment of Multiple Myeloma (MM) patients with its investigational product oNKord®.